Quantcast

Industry news that matters to you.  Learn more

Michael J. Fox Foundation Announces $1.1 Million to Advance Leading Biomarker Candidates for Parkinson’s Disease

The Michael J. Fox Foundation for Parkinson’s Research today announced nearly $1.1 million for projects aimed at advancing the development of leading biomarker candidates for Parkinson’s disease. The discovery and validation of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials.

TcLand Teams Up with Spanish Institute to Develop Assay for Predicting Response To TNFalpha Therapy

TcLand Expression is teaming up with the Hospital Vall d-Hebron Research Institute (HVIR) in Spain to develop a biomarker-based assay for predicting individual patients’ responses to TNFα blocker therapy for rheumatoid arthritis (RA). The collaboration agreement gives TcLand exclusive, worldwide rights to HVIR’s IP covering response-related biomarkers discovered by the Institute’s Sara Marsal, M.D., director of the Grup de Recerca de Reumatologia.

Duke, LabCorp Launch ‘Factory’ to Translate Biomarkers into Personalized Medicine Tests

If a factory is where raw components are manufactured and assembled into commercial products, then why not take a similar approach to developing diagnostics to predict disease predisposition and response to drugs?

Duke University and the Laboratory Corporation of America have put their collective expertise together to create just such an enterprise, which they’ve dubbed the Biomarker Factory. The project, announced earlier this month, enjoins Duke University Medical Center’s expertise in biomarker discovery and LabCorp’s capacity to develop laboratory-developed tests from validated biomarkers.